The Comprehensive Oncology Board Review is a highly regarded and comprehensive program designed to provide an in-depth review of the diagnosis, staging, and management of neoplastic diseases. This on-demand board review program covers both solid tumor oncology and hematologic oncology, making it a valuable resource for medical oncology professionals, including physicians, nurses, pharmacists, fellows, and residents.
Program Outline:
SOLID TUMOR SESSION:
Colon Cancer – Leonard B. Saltz, MD
Melanoma – Paul B. Chapman, MD
Prostate Cancer – Susan F. Slovin, MD, PhD
Kidney Cancer – Robert J. Motzer, MD
Urothelial Cancer – Gopa Iyer, MD
Testis Cancer – Darren R. Feldman, MD
Uterine/Cervix/Other GYN Cancers – Carol Aghajanian, MD
Ovarian Cancer – Rachel N. Grisham, MD
Breast Cancer: Surgery – Hiram S. Cody III, MD, FACS
Breast Cancer: Radiation Therapy – Beryl McCormick, MD, FACR
Genetics – Zsofia K. Stadler, MD
Small Cell Lung Cancer – W. Victoria Lai, MD
Breast Cancer: Adjuvant Therapy – Chau T. Dang, MD
Breast Cancer: Advanced Disease – Rachel Sanford, MD
Breast Cancer: Hormonal Therapy – Julia Brockway-Marchello, MD
Carcinoma of Unknown Primary – Anna M. Varghese, MD
Hepatocellular Cancer and Cholangiocarcinoma – Ghassan K. Abou-Alfa, MD, MBA
Pancreatic and Neuroendocrine Cancer – Eileen M. O’Reilly, MD
Non-Small Cell Lung Cancer – Gregory J. Riely, MD, PhD
Head and Neck, Thyroid, Non-Melanoma Skin Cancer – Lara A. Dunn, MD
Anal/Rectal Cancer – Andrea Cercek, MD
Esophageal/Gastric Cancer – David H. Ilson, MD, PhD, FACP, FASCO
CNS Tumors – Christian Grommes, MD
Sarcoma – Mark A. Dickson, MD
Infectious Disease – Susan K. Seo, MD
Mesothelioma – Marjorie G. Zauderer, MD
Pharmacology – Mrinal M. Gounder, MD
MALIGNANT HEMATOLOGY SESSION:
28. CAR T cells – Michael Scordo, MD
Low-Grade NHL – Andrew D. Zelenetz, MD, PhD
CLL/SLL – Lindsey Roeker, MD
DLBCL/MCL/BL – Paul Hamlin, MD
HL/T Cell – Alison J. Moskowitz, MD
Auto/Allo – Gunjan Shah, MD
ALL – Mark Blaine Geyer, MD
AML – Eytan Stein, MD
MDS/MPN – Michael J. Mauro, MD
Myeloma/Amyloid – Malin Hultcrantz
BENIGN HEMATOLOGY SESSION:
38. Approach to The Bleeding Patient – Rekha Paramewaran, MD
The Role of the New Direct Oral Anticoagulants in Practice – Simon Mantha, MD, MPH
Thrombocytopenia, ITP and Beyond – Cy Wilkins, MD
Sickle Cell Disease, Thalassemia – Jodi Mones, MD
Key Objectives:
Define the state-of-the-science in the diagnosis, staging, and therapeutic management of solid tumor cancers and hematologic cancers.
Discuss recent treatment advances in solid tumor and hematologic oncology and apply knowledge gained in modern clinical practice.
Prepare for ABIM examinations in medical oncology and hematology.
Program Details:
Recorded/Review Date: March 11-14, 2022
Original Release Date: April 4, 2022
Termination Date: December 31, 2022
This program provides a comprehensive and up-to-date review of oncology topics, making it an invaluable resource for medical professionals seeking to enhance their knowledge and prepare for board examinations.
